Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-27
DOI
10.1038/s41598-022-18871-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
- (2021) Josep Tabernero et al. Future Oncology
- Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
- (2021) TETSUO ISHIZAKI et al. ANTICANCER RESEARCH
- Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
- (2021) T. Takahashi et al. ESMO Open
- The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
- (2021) HIDEKAZU KURAMOCHI et al. ANTICANCER RESEARCH
- Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
- (2021) Ana Fernández Montes et al. Scientific Reports
- Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
- (2020) T. Yoshino et al. ANNALS OF ONCOLOGY
- TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
- (2020) Per Pfeiffer et al. LANCET ONCOLOGY
- Phase Ib/ II Study of Biweekly TAS ‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies ( BiTS Study)
- (2020) Hironaga Satake et al. ONCOLOGIST
- Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study
- (2020) Yohei Nose et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
- (2020) Yoichiro Yoshida et al. International Journal of Clinical Oncology
- Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
- (2020) Josep Tabernero et al. ESMO Open
- Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
- (2019) Hironori Fujii et al. ONCOLOGIST
- Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population‐based analysis
- (2019) Jiwei Wang et al. Cancer Medicine
- Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
- (2019) Daisuke Kotani et al. BMC CANCER
- Multiple treatment lines and prognosis in metastatic colorectal cancer patients
- (2018) Chiara Carlomagno et al. CANCER AND METASTASIS REVIEWS
- Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
- (2018) Jianming Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study
- (2018) Lin Yang et al. Aging-US
- TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
- (2017) Yasutoshi Kuboki et al. LANCET ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
- (2016) Pashtoon M. Kasi et al. BMC CANCER
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
- (2012) Takayuki Yoshino et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now